Julian Baker and Felix Baker’s Baker Bros. Advisors have disclosed in a new filing with the SEC adding approximately 4,100 shares to their stake in Genomic Health, Inc. (NASDAQ:GHDX). Julian and Felix Bakers received the securities instead of director retainer fees of $10,000. Baker Bros. currently holds a total of over 13.84 million shares of the company.
Molecular diagnostics company, Genomic Health, Inc. (NASDAQ:GHDX) is engaged in the development of genomic-based laboratory services that analyze the biology of cancer for providing individualized treatment decisions. Earlier, the company entered into an agreement with Almac Group, under the terms of which, Genomic will license Almac’s technology to develop and commercialize a multi-gene test to predict benefit from chemotherapy drugs.
For the third quarter of 2013, Genomic Health, Inc. (NASDAQ:GHDX) reported revenue of $66 million, up from $58.6 million in the same period of 2012. The company also posted a net income of $0.5 million, down from $3.7 million, a year ago.
Baker Bros. are some of the largest shareholders of Genomic Health, Inc. (NASDAQ:GHDX). Millennium Management, led by Israel Englander, in its latest 13F, disclosed ownership of some 195,300 shares, worth $5.97 million. Another shareholder is Ken Griffin’s Citadel Investment Group, which held 108,700 shares, with a reported value of $3.32 million.
Aside from Genomic Health, Inc. (NASDAQ:GHDX), Baker Bros. also recently disclosed holding approximately 5.26 million shares of Celsus Therapeutics PLC (ADR) (OTCMKTS:CLSXD). The stake amasses 13.1% of the company’s common stock. Celsus Therapeutics is a development company that specializes on novel anti-inflammatory drugs.
Earlier, Baker Bros. reported about trimming their stake in MEI Pharma Inc (NASDAQ:MEIP) to some 746,500 shares, from 1.13 million held previously.